- On March 18, 2026, Core Scientific, Inc. amended its delayed-draw bridge credit agreement, doubling total term loan commitments to US$1.00 billion and drawing the additional US$500.00 million to fund data center infrastructure, equipment, land, and energy procurement.
- This sizeable, fully drawn facility backed by Morgan Stanley and JPMorgan underscores lenders’ confidence in Core Scientific’s expansion plans and capital-intensive AI and high-performance computing ambitions.
- Next, we’ll examine how accessing an expanded US$1.00 billion credit facility might reshape Core Scientific’s investment narrative and risk profile.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Core Scientific Investment Narrative Recap
To own Core Scientific, you need to believe its pivot from Bitcoin mining to AI and high-performance compute can offset past losses and execution setbacks. The expanded US$1.00 billion bridge facility intensifies the key near term catalyst of building out data center capacity, while also magnifying the main risk around leverage, capital deployment discipline, and the company’s ability to earn an adequate return on this new debt-funded buildout.
The most relevant recent announcement is the US$500.0 million initial 364 day loan facility closed on March 5, 2026, which set up the accordion that has now been fully tapped. Together, these financings frame how quickly Core Scientific is committing capital to data center infrastructure relative to its CoreWeave-backed growth plans, sharpening both the upside from contracted HPC revenue and the risk if utilization or customer diversification fall short.
Yet this funding push also raises fresh questions about concentration risk and future refinancing needs that investors should be aware of...
Read the full narrative on Core Scientific (it's free!)
Core Scientific's narrative projects $1.5 billion revenue and $439.9 million earnings by 2029.
Uncover how Core Scientific's forecasts yield a $26.40 fair value, a 57% upside to its current price.
Exploring Other Perspectives
Before this new US$1.00 billion facility, the most optimistic analysts were already projecting about US$1.8 billion of revenue and roughly US$641.5 million of earnings by 2028, so it will be important for you to weigh how that bullish view on low risk, capital light contracts might change in light of Core Scientific now leaning harder on short term debt to build out its AI data center footprint.
Explore 3 other fair value estimates on Core Scientific - why the stock might be worth just $26.40!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Core Scientific research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- Our free Core Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Core Scientific's overall financial health at a glance.
Curious About Other Options?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com